Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Calgary, Calgary, AB, Canada.
Department of Otolaryngology-Head and Neck Surgery; University of Virginia School of Medicine, Charlotteville, VA.
Int Forum Allergy Rhinol. 2017 Oct;7(10):937-944. doi: 10.1002/alr.21998. Epub 2017 Aug 11.
Improving the quality of healthcare is a complex and resource intensive process. To optimize the allocation of scarce resources, quality improvement (QI) should focus on high-value diseases that will produce the largest improvement in health system performance. Given the breadth and multidisciplinary nature of sinonasal disease management, the purpose of this study was to transparently develop a prioritized list of sinonasal diseases for QI from the perspective of the specialty of rhinology and the American Rhinologic Society (ARS).
The RAND modified Delphi methodology was used to rank the priority of nine sinonasal disease categories from 1 (lowest priority) to 9 (highest priority). Two rounds of ranking along with a teleconference meeting was performed by a panel of 9 experts from the ARS Quality Improvement Committee.
The final QI-prioritized list of sinonasal diseases are as follows: chronic rhinosinusitis (CRS) (mean score = 8.9), recurrent acute rhinosinusitis (RARS) (mean score = 7.9), sinonasal neoplasms (mean score = 7.0), anatomic nasal obstruction (mean score = 5.9), refractory epistaxis (mean score = 5.2), complicated acute rhinosinusitis (mean score = 5.2), chronic nonallergic rhinitis (mean score = 4.4), orbital disease (mean score = 4.3), uncomplicated acute rhinosinusitis (mean score = 4.1), and allergy/allergic rhinitis (mean score = 3.7).
The three most important disease categories for QI from the perspective of the specialty of rhinology were CRS, RARS, and sinonasal neoplasms. Future studies need to define and validate quality metrics for each of these important disease categories in order to facilitate appropriate measurement and improvement initiatives.
提高医疗保健质量是一个复杂且资源密集型的过程。为了优化稀缺资源的分配,质量改进(QI)应侧重于高价值疾病,这些疾病将对卫生系统绩效的改善产生最大影响。鉴于鼻窦疾病管理的广泛和多学科性质,本研究旨在从鼻科学专业和美国鼻科学学会(ARS)的角度,透明地制定鼻窦疾病 QI 的优先清单。
使用 RAND 改良 Delphi 方法对 9 种鼻窦疾病类别进行排名,从 1(优先级最低)到 9(优先级最高)。由来自 ARS 质量改进委员会的 9 名专家组成的小组进行了两轮排名和电话会议。
最终的 QI 优先鼻窦疾病清单如下:慢性鼻-鼻窦炎(CRS)(平均得分= 8.9)、复发性急性鼻-鼻窦炎(RARS)(平均得分= 7.9)、鼻窦肿瘤(平均得分= 7.0)、解剖性鼻阻塞(平均得分= 5.9)、难治性鼻出血(平均得分= 5.2)、复杂急性鼻-鼻窦炎(平均得分= 5.2)、慢性非变应性鼻炎(平均得分= 4.4)、眼眶疾病(平均得分= 4.3)、单纯性急性鼻-鼻窦炎(平均得分= 4.1)和过敏/变应性鼻炎(平均得分= 3.7)。
从鼻科学专业的角度来看,QI 的三个最重要的疾病类别是 CRS、RARS 和鼻窦肿瘤。未来的研究需要为这些重要疾病类别中的每一个定义和验证质量指标,以促进适当的测量和改进举措。